Trial Profile
A randomized, controlled pivotal Phase 3 clinical trial comparing the combination of oral rigosertib plus azacitidine to azacitidine plus placebo in high risk myelodysplastic syndrome patients
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 01 Dec 2019
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Rigosertib (Primary)
- Indications Myelodysplastic syndromes
- Focus Registrational; Therapeutic Use
- Sponsors Onconova Therapeutics
- 06 Nov 2019 Trial design data of this trial was released in the 61st Annual Meeting and Exposition of the American Society of Hematology.
- 24 Oct 2019 According to an Onconova Therapeutics media release, company plan to consult with key opinion leaders on the design the study for submission to the FDA as the next step in the development of oral rigosertib. The proposed study does not require a Special Protocol Assessment (SPA).
- 14 Aug 2019 According to an Onconova Therapeutics media release, the company expects completion of the FDA SPA decision before the end of 2019.